|

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

RECRUITINGSponsored by Kyverna Therapeutics
Actively Recruiting
SponsorKyverna Therapeutics
Started2025-11-24
Est. completion2041-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07403188

Summary

The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product). This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Provided informed consent for the LTFU study
* Received at least 1 infusion of KYV-101 as part of a previous KYV-101 parent treatment protocol

Exclusion Criteria:

* Not applicable

Conditions9

ArthritisDermatomyositisLupusMultiple SclerosisMyasthaenia GravisRefractory Lupus NephritisRheumatoid Arthritis (RAStiff-Person SyndromeSystemic Sclerosis (SSc)

Locations1 site

University of Colorado, Denver
Denver, Colorado, 80045
Study Coordinator

Browse More Trials

Arthritis trialsMultiple Sclerosis trialsLupus trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.